XERS NASDAQ
Credit Risk of going bust: higher than 53% of companies Debt: 13.5% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.86B.
Distance to default 4.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Chicago, IL 60607
US
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pieper Steven | S-Sale | 5,000 | $9.41 | 2026-10-01 |
| McCulloch Kevin | S-Sale | 15,000 | $9.41 | 2026-10-01 |
| Hecht Beth | S-Sale | 16,666 | $9.41 | 2026-10-01 |
| McCulloch Kevin | S-Sale | 25,000 | $10.00 | 2026-09-28 |
| McCulloch Kevin | S-Sale | 15,000 | $8.49 | 2026-09-01 |